BusinessOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with CirrhosisBy Nasdaq OMXJan 5, 2017, 2:05 PM UTC
BusinessAkari Therapeutics Expands Clinical and Regulatory Teams with Industry VeteransBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessActinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical ProgramsBy Nasdaq OMXDec 19, 2016, 12:00 PM UTC
BusinessActinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-ABy Nasdaq OMXDec 13, 2016, 12:00 PM UTC
BusinessOcera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic EncephalopathyBy Nasdaq OMXDec 7, 2016, 2:05 PM UTC
